GlassScriptPhysician profile
James Thomas Willmore
NPI 1770014516
$1,988.56
in general payments reported to CMS, 2019-2025
14 companies · $32.04 in 2025
The $32.04 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $419 · 2021: $48.79 · 2022: $236 · 2023: $160 · 2024: $1,093 · 2025: $32.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $893 · Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $892.75 |
| Food and Beverage | $392.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $994.11 | 2024-2025 | Apex 3d, Portfolio, Precision Mis Bunion |
| Active Medical, LLC | $441.12 | 2020-2023 | |
| Stryker Corporation | $161.71 | 2022-2023 | Citrefix, Salvation |
| Amgen INC. | $97.52 | 2024 | Krystexxa |
| Medtronic, INC. | $72.68 | 2022-2024 | Venaseal |
| Smith+Nephew, INC. | $69.30 | 2021-2023 | Grafix Pl |
| Abbvie INC. | $50.28 | 2022-2023 | Dalvance |
| Organogenesis INC. | $17.87 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.25 | 2025 | |
| Kci USA, INC. | $15.80 | 2021 | |
| Nalu Medical, INC. | $14.57 | 2022 | |
| Boston Scientific Corporation | $13.91 | 2023 | Wavewriter Alpha Prime 16 |
| Paratek Pharmaceuticals, INC. | $13.81 | 2022 | |
| Curonix LLC | $8.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Willmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.